top of page
By The Business Times
2 Jan 2025
MEDTECH startup Lucence has received expanded Medicare approval for its LiquidHallmark cancer test to include the reimbursement for circulating tumour RNA analysis, under the United States’ federal health insurance programme.
This follows the 2023 approval of the cancer test for circulating tumour DNA analysis under Medicare.
The company now stands as the only provider with Medicare coverage for a test that combines both circulating tumour DNA and RNA analyses, Lucence said on Thursday (Jan 2).
bottom of page